Antimicrobial Surveillance programs have become an integral component of our understanding of resistance. Effective surveillance programs will serve as an early warning device to detect emerging problems, monitor changing patterns of resistance, help guide appropriate antimicrobial therapy based on susceptibility data, and identify and predict gaps in the availability of existing drugs to help industry and government target the development of new compounds.

JMI Laboratories directs many surveillance programs, including one of the world's largest, the SENTRY Antimicrobial Surveillance Program. Greater than 30,000 unique isolates annually are sent and processed through JMI Laboratories from its extensive network of participating hospitals and medical centers from around the world dating back to 1997. Additional requested surveillance studies can be created as stand-alone programs or can be incorporated into the broader SENTRY Program platform.

Click here to view slides from 2006 Gordon Research Conference on New Antibacterial Discovery & Development.

Additional information on these topics can be found in JMI's on-line Scientific Presentations and Bibliography. Click here to search.



JMI Laboratories
345 Beaver Kreek Centre, Suite A, North Liberty, Iowa 52317
tel 319.665.3370     fax 319.665.3371

Send comments or questions to the site webmaster